104 related articles for article (PubMed ID: 31306192)
1. Incidental Finding of Acute Lymphocytic Leukemia in a Prostate-Specific Membrane Antigen PET/CT.
Acksteiner C; Sounness B
Clin Nucl Med; 2019 Sep; 44(9):e529-e531. PubMed ID: 31306192
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Incidentally Detected 18F-PSMA Uptake in Glomus Jugulare.
Zade A; Trivedi C; Ingule A; Jha S; Agrwal A
Clin Nucl Med; 2020 Aug; 45(8):e360-e362. PubMed ID: 32520502
[TBL] [Abstract][Full Text] [Related]
4. Incidental Detection of Radiotracer Uptake in Intracranial Dermoid Cyst on 18F-Prostate-Specific Membrane Antigen PET/CT During Staging for Prostate Carcinoma.
Hod N; Levin D; Novoa R; Lantsberg S
Clin Nucl Med; 2021 May; 46(5):e273-e275. PubMed ID: 33323739
[TBL] [Abstract][Full Text] [Related]
5. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
7. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop.
Gupta M; Choudhury PS; Rawal S; Goel HC; Singh A; Talwar V; Sahoo SK
Hell J Nucl Med; 2017; 20 Suppl():156. PubMed ID: 29324926
[TBL] [Abstract][Full Text] [Related]
9. Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor.
Vamadevan S; Le K; Shen L; Ha L; Mansberg R
Clin Nucl Med; 2017 Jul; 42(7):560-562. PubMed ID: 28481797
[TBL] [Abstract][Full Text] [Related]
10. A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.
Ladwa R; Gustafson S; McCaffrey E; Miles K; O'Byrne K
Clin Nucl Med; 2017 Jun; 42(6):e311-e312. PubMed ID: 28240670
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
12. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma.
Haemels M; Jentjens S; Cleeren F; Sciot R; Lambert J; Van Laere K; Goffin K
Hell J Nucl Med; 2020; 23(1):79-80. PubMed ID: 32222733
[TBL] [Abstract][Full Text] [Related]
13. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
14. Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT.
Soydal C; Ozkan E; Yerlikaya H; Utkan G; Kucuk ON
Clin Nucl Med; 2016 Jun; 41(6):e294-5. PubMed ID: 26909710
[TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
17. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
19. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
20. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
